ES2286237T3 - Cristales de un derivado nucleosido de pirimidina. - Google Patents

Cristales de un derivado nucleosido de pirimidina. Download PDF

Info

Publication number
ES2286237T3
ES2286237T3 ES02711347T ES02711347T ES2286237T3 ES 2286237 T3 ES2286237 T3 ES 2286237T3 ES 02711347 T ES02711347 T ES 02711347T ES 02711347 T ES02711347 T ES 02711347T ES 2286237 T3 ES2286237 T3 ES 2286237T3
Authority
ES
Spain
Prior art keywords
compound
angstroms
crystalline form
formula
ray
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02711347T
Other languages
English (en)
Spanish (es)
Inventor
Takashi SANKYO COMPANY LIMITED TAKITA
Keiichi SANKYO COMPANY LIMITED OHTSUKA
Eiji SANKYO COMPANY LIMITED NUMAGAMI
Susumu SANKYO COMPANY LIMITED HARASHIMA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sankyo Co Ltd
Original Assignee
Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co Ltd filed Critical Sankyo Co Ltd
Application granted granted Critical
Publication of ES2286237T3 publication Critical patent/ES2286237T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES02711347T 2001-02-09 2002-02-06 Cristales de un derivado nucleosido de pirimidina. Expired - Lifetime ES2286237T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001033128 2001-02-09
JP2001-33128 2001-02-09

Publications (1)

Publication Number Publication Date
ES2286237T3 true ES2286237T3 (es) 2007-12-01

Family

ID=18896929

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02711347T Expired - Lifetime ES2286237T3 (es) 2001-02-09 2002-02-06 Cristales de un derivado nucleosido de pirimidina.

Country Status (21)

Country Link
EP (1) EP1364959B1 (https=)
JP (2) JP3748536B2 (https=)
KR (1) KR100679904B1 (https=)
CN (1) CN100408591C (https=)
AT (1) ATE361929T1 (https=)
AU (1) AU2002230164B2 (https=)
BR (2) BR0207102A (https=)
CA (1) CA2437994C (https=)
CY (1) CY1106685T1 (https=)
CZ (1) CZ303241B6 (https=)
DE (1) DE60220024T2 (https=)
DK (1) DK1364959T3 (https=)
ES (1) ES2286237T3 (https=)
HU (1) HU229294B1 (https=)
IL (2) IL157216A0 (https=)
MX (1) MXPA03007123A (https=)
NZ (1) NZ527393A (https=)
PT (1) PT1364959E (https=)
RU (1) RU2256666C2 (https=)
WO (1) WO2002064609A1 (https=)
ZA (1) ZA200306121B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070101408A (ko) 1999-09-02 2007-10-16 이비덴 가부시키가이샤 프린트배선판 및 프린트배선판의 제조방법
CN100381027C (zh) 1999-09-02 2008-04-09 伊比登株式会社 印刷布线板及其制造方法
GB0526419D0 (en) * 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
JP5066737B2 (ja) * 2007-04-06 2012-11-07 大鵬薬品工業株式会社 シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) * 2008-05-08 2008-06-18 Cyclacel Ltd Process
AU2009259136B2 (en) 2008-06-09 2014-09-25 Cyclacel Limited Combinations of sapacitabine or CNDAC with DNA methyltransferase inhibitors such as decitabine and procaine
PL2696878T3 (pl) 2011-04-14 2020-01-31 Cyclacel Limited Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej
CA2866852C (en) * 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
KR102629310B1 (ko) 2015-03-09 2024-01-24 더블유.알. 그레이스 앤드 캄파니-콘. 니코틴아미드 리보사이드의 결정 형태
EP3727400A4 (en) 2017-12-22 2021-10-20 Elysium Health, Inc. CRYSTALLINE FORMS OF NICOTINAMIDE RIBOSIDE CHLORIDE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) * 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
FI105556B (fi) * 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta

Also Published As

Publication number Publication date
BR0207102A (pt) 2004-01-27
AU2002230164B2 (en) 2005-04-07
CY1106685T1 (el) 2012-05-23
HUP0303159A2 (hu) 2003-12-29
DK1364959T3 (da) 2007-06-04
DE60220024D1 (en) 2007-06-21
RU2256666C2 (ru) 2005-07-20
BRPI0207102A8 (pt) 2018-02-27
JP4356998B2 (ja) 2009-11-04
CA2437994C (en) 2011-05-17
JP3748536B2 (ja) 2006-02-22
WO2002064609A1 (en) 2002-08-22
EP1364959B1 (en) 2007-05-09
IL157216A (en) 2008-03-20
IL157216A0 (en) 2004-02-19
DE60220024T2 (de) 2007-11-22
EP1364959A1 (en) 2003-11-26
EP1364959A4 (en) 2004-03-24
HU229294B1 (en) 2013-10-28
NZ527393A (en) 2004-07-30
ATE361929T1 (de) 2007-06-15
KR100679904B1 (ko) 2007-02-07
RU2003124648A (ru) 2005-02-27
PT1364959E (pt) 2007-07-23
JP2002308895A (ja) 2002-10-23
CZ303241B6 (cs) 2012-06-13
CN1501939A (zh) 2004-06-02
MXPA03007123A (es) 2003-11-18
ZA200306121B (en) 2005-01-26
KR20030081424A (ko) 2003-10-17
CA2437994A1 (en) 2002-08-22
CZ20032111A3 (cs) 2003-12-17
JP2006008699A (ja) 2006-01-12
HUP0303159A3 (en) 2007-06-28
CN100408591C (zh) 2008-08-06

Similar Documents

Publication Publication Date Title
ES2316650T3 (es) Polimorfos de hidrogenosulfato de clopidogrel.
ES2929200T3 (es) Tienopirroles sustituidos como inhibidores de PAD4
ES2754548T3 (es) Forma cristalina de bisulfato inhibidor de quinasa JAK y un método de preparación del mismo
ES2772498T3 (es) Preparación de un inhibidor mek y formulación que comprende el mismo
ES2286237T3 (es) Cristales de un derivado nucleosido de pirimidina.
WO2021244323A1 (zh) 一种乌帕替尼的晶型及其制备方法和用途
ES2528202T3 (es) Una forma cristalina de tigeciclina y procesos para su preparación
CN114206878B (zh) 乌帕替尼的晶型及其制备方法和用途
CN101597272B (zh) 艾拉莫德的钾盐化合物,其制备方法和药物应用
US6908906B2 (en) Crystalline forms of pyrimidine nucleoside derivative
ES2829578T3 (es) Polimorfo cristalino de acetato de 15ß-hidroxi-osaterona
BR112021008732A2 (pt) ingredientes farmacêuticos amorfos ativos compreendendo carbonato de magnésio mesoporoso substancialmente amorfo
ES2228848T3 (es) Formas hidratadas y cristalinas de un compuesto de acido neuraminico.
JP7503063B2 (ja) 神経変性疾患の治療のための2-フッ素化胆汁酸
WO2018076783A1 (zh) 右旋奥拉西坦晶型ii及其制备方法和用途
CN115572298A (zh) 一种核苷类似物及其盐的晶型、制备方法和应用
WO2014139447A1 (zh) (1s)-1-[4-氯-3-(4-乙氧基苄基)苯基]-1,6-二脱氧-d-葡萄糖的晶型a及其制备方法和应用
ES2346858T3 (es) Sustancia amorfa de un derivado triciclico de triazolobenzazepina.
WO2018113592A1 (zh) 4'-硫代-2'-氟代核苷磷酰胺化合物的固体形式及其制备方法和用途
CN105753869A (zh) 一种cdk抑制剂和mek抑制剂的共晶及其制备方法
AU2013321890B2 (en) Crystalline polymorphic form of ulipristal acetate
JP2026048666A (ja) インドール化合物の固体形態、その調製方法及びその使用
HK40129060A (zh) 取代n-(4-三氟甲基)-2-氰基巴豆酰胺化合物及其制备方法、药物组合及用途
ES2357885T3 (es) FORMAS POLIMORFAS DE N-(2,3-DIMETIL-5,6,7,8-TETRAHIDROFURO[2,3-b]QUINOLÍN-4-IL)-2-(2-OXOPIRROLIDÍN-1-IL)ACETAMIDA.
CN112047990A (zh) 阿糖胞苷前药mb07133晶型及其应用